Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 05, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 05, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg".